| INTRODUCTION
Doxorubicin (DOX) is an anthracycline antitumor antibiotic used to treat many malignancies in dogs and people, including lymphoma, osteosarcoma, soft tissue sarcoma, histiocytic sarcoma, and carcinomas. 1, 2 Repeated doses of DOX can result in potentially life-threatening cardiotoxicity in both species. 3, 4 Clinical findings of cardiotoxicity include arrhythmias and decreased systolic function, resulting in a disease resembling dilated cardiomyopathy (DCM). However, electrocardiographic abnormalities do not correlate with the severity of cardiomyopathy. 5, 6 Moreover, not all individuals with echocardiographic or electrocardiographic abnormalities will develop clinical signs of cardiac disease, such as syncope or congestive heart failure. 5, [7] [8] [9] Acute arrhythmias during administration also can be seen and do not correlate with chronic toxicity. 5, 7 Histopathologic findings of chronic irreversible cardiotoxicity include myofibrillary atrophy and degeneration, interstitial edema and fibrosis, swelling of the sarcoplasmic reticulum, and cytoplasmic vacuolation, although these findings are difficult to distinguish from other cardiac diseases. 2, 7, 10 Abbreviations: 2DE, 2-dimensional echocardiography; ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; DOX, doxorubicin; MST, median survival time; VPC, ventricular premature contraction.
In humans, factors known to increase risk of cardiotoxicity include cumulative doses of DOX greater than 300 mg/m 2 , advanced (>70 years old) or young (<15 years old) age. 11, 12 Before radiation to the chest wall, coadministration with other cytotoxic agents (particularly cyclophosphamide), hypertension, diabetes mellitus, active congestive heart failure, preexisting cardiac disease, history of myocardial infarction within 1 year, and previous anthracycline administration all increase the risk of DOX cardiotoxicity. 11 Cardiotoxicity typically develops within 6 months after completion of treatment but has been observed several years after DOX treatment. [13] [14] [15] Measures to prevent cardiotoxicity include administering the drug over a longer duration of time (>6 hours)
or coadministering the cardioprotective drug dexrazoxane. 16, 17 Known risk factors that predispose dogs receiving DOX to devel- Administration of DOX over a 1-hour time period resulted in a lower incidence of ECG abnormalities (12%) as compared to a historical population of dogs that received the drug over a 10-minute time period (17.7%). 18 In this study, 63% of the ECG abnormalities were ventricular premature contractions (VPCs), which usually did not require medical treatment, whereas 2 and 3 dogs developed Grade II and III arrhythmias, respectively. These abnormalities were noted during the course of treatment (5.3%) and from 94 to 1339 days after treatment (6.7%). However, the effect of a 1-hour infusion on the development of clinical cardiotoxicity (congestive heart failure or other clinical signs) was not described. Historically, at our institution, DOX has been administered either as a short 10-15 minutes infusion or as a longer 1-hour infusion, depending on clinician preference or if the dogs were considered high-risk breeds for DCM (Boxers, Doberman Pinschers, Great Danes, Irish Wolfhounds, Newfoundlands, or Cocker Spaniels). 19 In addition, because dexrazoxane is safe and well tolerated when coadministered with DOX in dogs and decreases the severity of histopathologic heart lesions in dogs receiving DOX, 10, 20, 21 we coadminister it based on clinician preference.
The aims of this retrospective study were to determine if the duration of DOX infusion influenced the incidence of cardiotoxicity, to characterize the incidence of clinical cardiotoxicity in dogs during or after DOX chemotherapy, and to identify any risk factors associated with cardiotoxicity. 
| MATERIALS AND METHODS

| Statistical evaluation
Chi-square analysis was used to compare the incidence of clinical cardiotoxicity in dogs receiving a 1-hour infusion of DOX with development of cardiotoxicity in dogs receiving a short infusion of DOX.
Similarly, Chi-square analysis also was used to determine potential risk 
| Doxorubicin treatment
The total number of doses ranged from 1 to 9 within the intended max- and melphalan). Eighty-four dogs also received radiation therapy, all of which received half-body radiation therapy for lymphoma after chemotherapy.
| Cardiac evaluation
Ninety-five (19%) dogs had heart murmurs noted during their first 
| Clinical cardiotoxicity
A total of 31/494 (6.3%) dogs developed cardiac clinical signs during or after DOX treatment. Eleven of these dogs had preexisting cardiac abnormalities based on an echocardiogram before initiation of DOX.
Two dogs had right atrial masses suspected to be hemangiosarcoma, and progression of tumor size assessed on echocardiogram was suspected to be the cause of these dogs' clinical signs. The remaining 9 dogs had preexisting mitral valve disease that progressed on subsequent echocardiograms, and led to development of clinical signs.
These 11 dogs were excluded from the group with clinical DOXinduced cardiotoxicity. For 1 dog, sudden death was the only cardiacrelated clinical sign, and because this dog was not necropsied, the actual cause of death could not be determined. This dog was included because sudden death previously has been reported as the only clinical sign of DOX cardiotoxicity. 22 Cases were analyzed again excluding dog breeds at high risk for DCM, resulting in an incidence of 3.0% (14/455). This was significantly lower than the incidence of 15.4% seen in high-risk DCM dog breeds (P < .001). Higher body weight and higher cumulative dose of DOX were associated with clinical cardiotoxicity (P = .02 and .02, respectively). Decrease in fractional shortening after 5 doses of DOX (but not after 3), when compared to baseline results, was also a risk factor (P = .02) for dogs not at high risk for DCM. These factors also were found to be significantly associated in multivariate analysis. 
Development of VPCs was not associated with cardiotoxicity in this
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FIGURE 3
Comparison of changes in fractional shortening after 3 and 5 doses of doxorubicin between dogs with cardiotoxicity (n = 20) and dogs without cardiotoxicity (n = 474). After 3 doses, dogs with cardiotoxicity had a mean 5.0% decrease and dogs without cardiotoxicity had a mean 1.7% increase) (P = .25). After 5 doses, dogs with cardiotoxicity had a mean 31.4% decrease and dogs without cardiotoxicity had a mean 2.1% decrease (P = .02). Horizontal dotted lines indicate means. *Statistically significant difference group (P = .43). No other risk factor was identified. Table 3 compares the different groups.
| DISCUSSION
In our study population, administration of DOX over 1 hour did not decrease the risk of clinical cardiotoxicity compared to a 10-15-minute infusion. In humans, a 6-hour infusion has been shown to decrease the risk of cardiotoxicity, as evidenced by a decrease in left ventricular ejection fraction, compared with a 15-20-minute infusion. 23 The 1-hour infusion, rather than a 6-hour infusion, was selected at our institution because it is the longest duration of administration chosen to balance the aim of extended administration while minimizing the risk of extravasation with extended chemotherapy administration, and a 1-hour infusion previously was shown to decrease the development of ECG signs of toxicity in dogs. 18 This duration of infusion may not be sufficient to prevent clinical cardiotoxicity in this patient population. Not enough dogs received dexrazoxane treatment to assess this treatment as a preventative measure.
The overall incidence of clinical cardiac disease secondary to confirmed or presumed DOX-induced cardiotoxicity in all patients receiving DOX was 4.0%. This incidence of clinical cardiac disease is similar to the reported incidence of 2.2% to 5.1% in people receiving DOX. 24, 25 Previous studies evaluating cardiotoxicity in dogs have found incidences of 2.3% to 17.7%, but the incidence has been reported to be as high as 29.8%. 9, 18, 26, 27 However, when examining the incidence of clinical cardiotoxicity, as manifested by the development of signs consistent with congestive heart failure, the results (4%-6.8%) are very similar to ours. The incidence of confirmed and suspected cardiotoxicity-related deaths in this population of dogs was 2.0% (10/494), although only 0.6% (3/494) could be confirmed on necropsy. The MST for patients after developing clinical signs in our study (29 days) was similar to the previously reported result of 26.5 days. 28 Other reported survival times include 48 hours and 90 days. 8, 9 The finding that dogs with clinical cardiotoxicity received a higher cumulative dose of DOX is not surprising given that the cardiotoxic effects of this drug are cumulative. The mean cumulative dose of 150 mg/m 2 of the affected dogs was similar to what has previously been reported. 9 Additionally, higher body weight was significantly associated with the development of clinical cardiotoxicity. Higher body weight previously has been suggested as a risk factor, 29 and therefore, larger dogs may be more likely to develop cardiotoxicity.
Because smaller dogs were dosed at 1 mg/kg, this finding also may be because of the fact that smaller dogs received lower cumulative doses, although multivariate analysis showed both higher body weight and higher cumulative dose to be significantly associated with cardiotoxicity. Doxorubicin-induced cardiomyopathy has many similarities with DCM, a disease that also has a higher incidence in large breed dogs. part of a downward trend, as it was for the majority of dogs in our study that developed clinical cardiotoxicity, concern for cardiac dysfunction is warranted. In the dogs that developed cardiotoxicity, the absolute value for the change in fractional shortening from baseline to that after 5 doses varied from 12.3% to 31%, with the majority of dogs having results below 28%, which is the cutoff for normal at our institution. Although it is difficult to determine an exact cutoff, decreases in fractional shortening of >15% from the baseline warrant concern for cardiotoxicity. In addition to decreases in fractional short- 
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